LGN vs TECH · rev $708.0M vs P/E 65, rev $1.22B
Legence Corp. Class A Common stock (LGN) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Legence Corp. Class A Common stock (LGN) is a engineering & construction company listed on NASDAQ.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported LGN revenue for 2025-09-30 was $708.0M. Net income was $379.0K. Revenue was up 26.2% from 2024-09-30 to 2025-09-30. LGN currently screens at market cap $14.66B.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
LGN currently screens at market cap $14.66B. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the LGN and TECH stock pages for the full models.
Not investment advice.